BMG Pharma S.r.l., a specialty pharmaceutical company, has announced the launch of its proprietary product Ialuxid gel in the People’s Republic of China. In its Chinese version, Ialuxid gel is a non-antibiotic antimicrobial gel that maintains a moist wound environment that is conducive to healing, especially suitable for post-surgical wounds. Following the approval of Ialuxid gel in China, Luqa Pharmaceuticals will start the roll out of the product across the entire territory through its nationwide coverage.

"Since the start of our cooperation for Ialuxid gel in China in May 2013, Luqa has worked hard to get the product to market in a record time" said Marco Mastrodonato, CEO of BMG Pharma S.r.l. "We are pleased to offer Ialuxid gel to new patients in China, who will receive the best care possible through our innovative delivery technology that provides fast relief to skin infections. This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world.”

“The launch of Ialuxid gel in China represents a big milestone for our company” said Robert Braithwaite, CEO of Luqa Pharmaceuticals. “Ialuxid gel is a great addition to our portfolio of skin solutions that aim at improving the quality of life of our patients. We are thankful for BMG’s support and we hope that this long-term collaboration will allow us to bring other of their key products to market in our territories.”

Ialuxid gel is a unique combination gel formulation which is registered in Europe to treat acne lesions, folliculitis, paronychia, Molluscum Contagiosum and impetigo. The key ingredients in this novel formulation - hyaluronic acid, glycine and hydrogen peroxide - it forms a protective film against external agents and prevents the bacterial infections due to the synergistic effects against a wide range of micro-organisms and to a protective and effective filmogenic barrier to the skin.